Close Menu

NEW YORK (GenomeWeb) – In 2018 a record number of new personalized therapies entered the market, there was greater adoption by oncologists of cancer diagnostics, including next-generation sequencing panels, and new regulatory and reimbursement policies emerged that recognize the importance of molecular tests to individualizing care.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.

Sep
25
Sponsored by
HalioDx

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers. 

Oct
03
Sponsored by
Agilent

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
08
Sponsored by
10x Genomics

This webinar will discuss a study that used spatial transcriptomics to gain insight into the molecular mechanisms of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.

Oct
10
Sponsored by
Roche

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.